Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefixime + lactic acid bacillus
- Development stage
- Unknown
- Lead developer
- Cosmas Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
cefixime + lactic acid bacillus is a fixed-dose combination therapy consisting of the third-generation cephalosporin antibiotic cefixime and the probiotic lactic acid bacillus (typically *Bacillus coagulans*). Cefixime exerts its bactericidal effect by binding to and inhibiting penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. This makes it effective against a broad spectrum of Gram-positive and Gram-negative pathogens. The inclusion of lactic acid bacillus is intended to prevent or treat antibiotic-associated dysbiosis and diarrhea by replenishing the beneficial gut microbiota that may be depleted during antibiotic treatment. This combination is commonly administered orally in tablet or dry syrup forms for various bacterial infections, including respiratory, urinary tract, and biliary tract infections.
- Brand names
- Zifi-LBTaxim-O LBCefigard-LBMilixim-LBCef-LB
- Other names
- Cefixime and Lactic Acid BacillusCefixime + Probiotic
02
Targets
PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on cefixime + lactic acid bacillus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefixime + lactic acid bacillus.